Adult Immune Thrombocytopenia Latest Advances

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.

Journal: Expert review of hematology

Published: April 08, 2026

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

Journal: The New England journal of medicine

Published: April 08, 2026

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Journal: Platelets

Published: April 01, 2026

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Journal: International journal of surgical pathology

Published: April 01, 2026

Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia.

Journal: Platelets

Published: March 31, 2026

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Journal: Pharmacological research

Published: March 31, 2026

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 30, 2026

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Journal: Expert opinion on pharmacotherapy

Published: March 24, 2026

Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis.

Journal: Nature reviews. Cardiology

Published: March 19, 2026

Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia.

Journal: Hematology (Amsterdam, Netherlands)

Published: March 17, 2026

Construction and evaluation of a thrombosis risk prediction model in patients with primary immune thrombocytopenia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 16, 2026

Adult Immune Thrombocytopenia Latest Advances

Find the Latest Research About Adult Immune Thrombocytopenia

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia.

Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia.

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis.

Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis.

Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia.

Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia.

Construction and evaluation of a thrombosis risk prediction model in patients with primary immune thrombocytopenia

Construction and evaluation of a thrombosis risk prediction model in patients with primary immune thrombocytopenia